Member Info for mbingo

If performance can be improved at Yanfolila, the upside in market cap should be tremendous! B2gold looks like a market cap of CAD 6bn+. Hum at £79m currently. Precious metals are looking strong so would be great to see performance outperform other small cap miners.

I’ve been building a position here from 880s. The balance sheet much stronger than when I last built a position. Juanicipio will boost production but even as we are and with precious metals in the 1700s and 25s, dividends of 20c produced. Positioned for silver to break through $29 properly, which I think will happen this year. Chinese news re allowing citizens to accumulate gold is great also for the space.

Thanks for this. I totally agree re the IP, FDA /CP approval. Significant investment/cost spent to get the business to this position. It is possible to see sales reach $25m for this year and $40-50m in 2022 (after all, sales from San Antonio to be up to $36m alone after expansion completed, before other revenue streams ). Even if we look at only 5 x 2022 sales, this is $200m market cap conservatively so 2.5x current market cap. Cash of £9.5m and chairman buying provide additional comfort. Cheap here.

Cannot find it. If you do track it down, please let me know. I could ask investor relations but they are a bit unresponsive!

Thanks, I’ll look for a link.

Thanks for this. Was the £30m target revenue number put in an RNS or was it Q&A with the company?

Phase 2 will add $35m sales estimated. Even if 3 x forward sales, looking at $150-200m or 3x current market cap. It’s cheap, without giving much though to IP.

Two late buys of 1.4m each at 4.2 and 4.4, plus 500k at 4.4 - this is re-rating!

And this should increase confidence in hospital procedures. Texas re-opening an important point!

Certainly a nice recovery on volume. Bodes well. Chunky 8m buy in there from earlier as well as late buying. Who’s buying?! Seller got to be out or close to.

Thanks, just viewed this. Certainly, valuation looks to be at base level. Forward looking market should see this challenge new highs in the not-too-distant. Hope we get news on additional commercial partnerships!

The last trading update was very robust I thought. Cash >£9m, revenue in line in spite of Covid. Orthopaedic division grew 10%. Costs being managed. Pick up in demand for biosurgery, Sam Antonio expansion to come on stream H1 2021 allowing for 50% increase in manufacturing capacity (cellright), commercial success leading to expected revenue increases. Moreover, chairman bought stock. It’s certainly fallen a long way. Think reversal has a long way to go, with immediate “open-up” upside and expansion plans to realise improved growth. For less £50m cap currently!

Would be good. Some cash on the books now, one project up and running and the other with near term upside. Directors well aligned with shareholders. Prices should firm.

Lot of value at this price. Re-rating happening now. Barely more than £20m cap.

It’s better on the app.

This is a great find - and a vindication of Metros strategy in this area.

Looks to set to break higher out of this range. Valuation certainly wrong at barely more than £200m cap. New CEO seems to be making the right decisions.

Added 50k shares today at 12.7, a screaming buy at this level imo; debt pile worked back with accelerating cash. Hedges were pared back towards year end and large upside from increase in Brent prices. Board well aligned with holders.

I’ve added today - market cap at these levels compelling.

I like: “ the product gross margin increased by 40bps to 62.7 per cent. (H1 FY20: 62.3 per cent.), a result of reduced discounting compared with H1 FY20, particularly online, and higher postage income.”